ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-13 18:00 |
Monthly information related to total number of voting rights and shares composi…
|
English | 235.3 KB | ||
| 2023-06-13 08:00 |
AKKADIAN PARTNERS REJECTS THE LIQUIDATION OF ERYTECH IN THE EVENT THAT THE MERG…
|
English | 178.5 KB | ||
| 2023-06-13 08:00 |
AKKADIAN PARTNERS DIT NON A LA LIQUIDATION D'ERYTECH EN CAS D'ECHEC DE LA FUSIO…
|
French | 201.5 KB | ||
| 2023-06-12 07:00 |
ERYTECH Responds to Akkadian’s Disinformation
|
English | 274.8 KB | ||
| 2023-06-12 07:00 |
ERYTECH répond à la désinformation d’Akkadian
|
French | 251.4 KB | ||
| 2023-06-07 07:30 |
Akkadian suggests to Erytech an alternative strategy to its merger with Pherecy…
|
English | 250.6 KB | ||
| 2023-06-07 07:30 |
Akkadian suggère à Erytech une stratégie alternative à sa fusion avec Pherecydes
|
French | 260.2 KB | ||
| 2023-06-05 08:00 |
ERYTECH annonce qu’Akkadian a initié une procédure visant à obtenir le report d…
|
French | 177.6 KB | ||
| 2023-06-05 08:00 |
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote …
|
English | 233.5 KB | ||
| 2023-05-25 10:53 |
Franchissement de seuils et déclaration d'intention
|
French | 293.4 KB | ||
| 2023-05-24 22:05 |
ERYTECH Announces the Availability of the Documents for its Annual General Meet…
|
English | 184.6 KB | ||
| 2023-05-24 22:05 |
ERYTECH annonce les modalités de mise à disposition des documents préparatoire…
|
French | 197.3 KB | ||
| 2023-05-23 22:05 |
ERYTECH annonce la mise à disposition du document d'exemption relatif au proje…
|
French | 211.1 KB | ||
| 2023-05-23 22:05 |
ERYTECH announces the availability of the exemption document relating to the pr…
|
English | 202.8 KB | ||
| 2023-05-16 18:00 |
Information mensuelle relative au nombre total de droits de vote et d’actions c…
|
French | 193.0 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
